Label: statrol- neomycin sulfate and polymyxin B sulfate solution

  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None

Drug Label Information

Updated May 12, 2006

If you are a consumer or patient please visit this version.

View All Sections
  • N/A - Section Title Not Found In Database

  • DESCRIPTION

    STATROL® (Neomycin and Polymyxin B Sulfates Ophthalmic Solution, USP) is a sterile ophthalmic drug combining two antibacterials in solution form.

    Each mL of solution contains: Active: Neomycin Sulfate equivalent to 3.5 mg Neomycin base, Polymyxin B Sulfate equal to 16,250 polymyxin B units.

    Preservative: Benzalkonium Chloride .004%. Vehicle: 0.5% Hydroxypropyl Methylcellulose 2910. Inactive: Boric Acid, Sodium Chloride, Hydrochloric Acid and/or Sodium Hydroxide (to adjust pH), Purified Water. DM-02

  • CLINICAL PHARMACOLOGY

    The anti-infective components in STATROL Ophthalmic Solution provide action against specific organisms susceptible to them. Polymyxin B Sulfate and Neomycin Sulfate are active in vitro against Staphylococcus aureus, Escherichia coli, Klebsiella/Enterobacter species, Neisseria species, Pseudomonas aeruginosa. This product does not provide adequate coverage against: Serratia marcescens, Streptococci, including Streptococcus pneumoniae.

  • INDICATIONS AND USAGE

    STRATOL Ophthalmic Solution is indicated in the topical treatment of infections of the external eye and its adnexa caused by susceptible bacteria. Such infections encompass conjunctivitis, keratitis, and keratoconjunctivitis, blepharitis and blepharoconjunctivitis, acute meibomianitis and dacryocystitis.

  • CONTRAINDICATIONS

    Epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, and many other viral diseases of the cornea and conjunctiva. Mycobacterial infection of the eye. Fungal diseases of ocular structures. Hypersensitivity to a component of the medication.

  • WARNINGS

    NOT FOR INJECTION INTO THE EYE. Should a sensitivity reaction occur, discontinue use. Neomycin Sulfate may cause cutaneous sensitization. Remove contact lenses before using.

  • PRECAUTIONS

    General

    As with other antibiotic preparations, prolonged use may result in overgrowth of nonsusceptible organisms, including fungi. If superinfection occurs, appropriate measures should be initiated. Whenever clinical judgment dictates; the patient should be examined with the aid of magnification, such as slit lamp biomicroscopy, and, where appropriate, corneal staining.

    Information for patients

    This product is sterile when packaged. To prevent contamination, care should be taken to avoid touching the bottle tip to eyelids or to any other surface. The use of this bottle by more than one person may spread infection. Keep bottle tightly closed when not in use. Keep out of the reach of children.

    Carcinogenesis, Mutagenesis, Impairment of Fertility

    Long-term studies in animals to evaluate carcinogenic or mutagenic potential have not been conducted with Polymyxin B Sulfate. Treatment of cultured human lymphocytes in-vitro with neomycin increased the frequency of chromosome aberrations at the highest concentrations (80 µg/mL) tested; however, the effects of neomycin on carcinogenesis and mutagenesis in humans are unknown.

    Polymyxin B Sulfate has been reported to impair the motility of equine sperm, but its effects on male or female fertility are unknown.

    Pregnancy

    Teratogenic Effects

    Pregnancy Category C. Animal reproduction studies have not been conducted with STATROL® (Neomycin and Polymyxin B Sulfates Ophthalmic Solution, USP). It is also not known whether Neomycin Sulfate and/or Polymyxin B Sulfate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. STATROL Ophthalmic Solution should be given to a pregnant woman only if clearly needed.

    Nursing Mothers

    It is not known whether these drugs are excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when STATROL Ophthalmic Solution is administered to a nursing mother.

  • ADVERSE REACTIONS

    Adverse reactions have occurred with the anti-infective components. Exact incidence figures are not available since no denominator of treated patients is available. Reactions occurring most often from the presence of the anti-infective ingredients are allergic sensitizations. (SEE WARNINGS.)

  • DOSAGE AND ADMINISTRATION

    Instill one or two drops in the lower conjunctival sac(s) three or more times daily as required.

  • HOW SUPPLIED

    STATROL (Neomycin and Polymyxin B Sulfates Ophthalmic Solution, USP) in 5 mL plastic DROP-TAINER® dispenser: NDC 0998-0623-05.

    STORAGE: Store at 46° - 80°F (8° - 27°C).

    Federal (USA) law prohibits dispensing without prescription.

    Alcon®
    OPHTHALMIC
    ALCON (Puerto Rico) INC.
    Humacao, Puerto Rico 00791 USA

    Revised: June 1995 
    Printed in USA
    238382

  • INGREDIENTS AND APPEARANCE
    STATROL 
    neomycin sulfate and polymyxin b sulfate solution
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:0998-0623
    Route of AdministrationOPHTHALMIC
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    neomycin sulfate (UNII: 057Y626693) (neomycin - UNII:I16QD7X297) 3.5 mg  in 1 mL
    polymyxin B sulfate (UNII: 19371312D4) (polymyxin B - UNII:J2VZ07J96K) 16250   in 1 mL
    Inactive Ingredients
    Ingredient NameStrength
    benzalkonium chloride ()  
    hydroxypropyl methylcellulose 2910 ()  
    boric acid (UNII: R57ZHV85D4)  
    sodium chloride (UNII: 451W47IQ8X)  
    hydrochloric acid (UNII: QTT17582CB)  
    sodium hydroxide (UNII: 55X04QC32I)  
    water (UNII: 059QF0KO0R)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:0998-0623-055 mL in 1 BOTTLE, PLASTIC
    STATROL 
    neomycin sulfate and polymyxin b sulfate solution
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:0065-0623
    Route of AdministrationOPHTHALMIC
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    neomycin sulfate (UNII: 057Y626693) (neomycin - UNII:I16QD7X297) 3.5 mg  in 1 mL
    polymyxin B sulfate (UNII: 19371312D4) (polymyxin B - UNII:J2VZ07J96K) 16250   in 1 mL
    Inactive Ingredients
    Ingredient NameStrength
    benzalkonium chloride ()  
    hydroxypropyl methylcellulose 2910 ()  
    boric acid (UNII: R57ZHV85D4)  
    sodium chloride (UNII: 451W47IQ8X)  
    hydrochloric acid (UNII: QTT17582CB)  
    sodium hydroxide (UNII: 55X04QC32I)  
    water (UNII: 059QF0KO0R)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:0065-0623-055 mL in 1 BOTTLE, PLASTIC
    Labeler - Alcon
View All Sections

Find additional resources

(also available in the left menu)

Safety

Report Adverse Events, FDA Safety Recalls, Presence in Breast Milk

Related Resources

Medline Plus, Clinical Trials, PubMed, Biochemical Data Summary

More Info on this Drug

View Labeling Archives, RxNorm, Get Label RSS Feed, View NDC Code(s)NEW!